Fluoxetine for Visual Recovery After Ischemic Stroke

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 02 Jun 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fluoxetine (Primary)
Indications Vision disorders
Focus Therapeutic Use
Acronyms FLUORESCE

Most Recent Events

01 Jun 2023 Primary endpoint has not been met (Improvement in size of visual field deficit (degrees)), according to Results published in the Journal of Neuro-Ophthalmology
01 Jun 2023 Results published in the Journal of Neuro-Ophthalmology
20 Aug 2020 According to clinicaltrials.gov the study was discontinued because of slow recruitment and lack of funding to expand to other sites.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight